Crossmark

Factors contributing to fidelity in a pilot trial of individualized resistant starches for pediatric inflammatory bowel disease: a fidelity study protocol

Crossref DOI link: https://doi.org/10.1186/s40814-021-00815-1

Published Online: 2021-03-19

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Castillo, Gisell

Mack, David R.

Lalu, Manoj M.

Singleton, Ruth

Fergusson, Dean A.

Stintzi, Alain

Harrison, Megan

Presseau, Justin https://orcid.org/0000-0002-2132-0703
Funding

Funding for this research was provided by:

Genome Canada (OGI-149)

Ontario Ministry of Economic Development and Innovation (13440)

Weston Foundation
License Information

Text and Data Mining valid from 2021-03-19

Version of Record valid from 2021-03-19
More Information

Article History

Received: 24 December 2020

Accepted: 9 March 2021

First Online: 19 March 2021

Declarations

:

: This study has received ethics approval from the Children’s Hospital of Eastern Ontario Research Ethics Board (ID # 20/65X). Individual consent will be obtained from all study participants.

: Not applicable.

: AS and DM are a co-founders of MedBiome, a clinical microbiomics company. The other authors have no competing interests to declare.

Document is current

Any future updates will be listed below